Japan has record 100,000 people aged over 100: How societies are ageing

Japan's centenarian population reached a record 107,677 in 2026, up 7,914 year over year, while its fertility rate fell to a record low 1.14 in 2025. Nearly 30% of residents are aged 65 or older, a share projected to approach 40% by 2070, as the total population is forecast to decline from a 2008 peak of about 128 million to 87 million by 2070. The demographic imbalance is intensifying labour shortages and raising pension, healthcare and elder-care costs against a shrinking tax and social-security contributor base.

Analysis

This is not a fresh earnings catalyst, but it reinforces a durable relative-growth divide inside Japan: labor-substitution suppliers should outgrow labor-intensive domestic service operators. FANUC (6954), Keyence (6861), SMC (6273) and Daifuku (6383) have operating leverage to wage inflation and factory/logistics automation demand; the more important second-order effect is that their addressable market expands from export manufacturing into domestic warehouses, food processing, construction and care facilities. Conversely, low-margin operators reliant on physical staffing face recurring wage pass-through constraints unless reimbursement or pricing frameworks adjust.

The fiscal transmission matters more for markets than the headline demographic statistic. Rising age-related spending narrows the government’s ability to offset household weakness through broad stimulus, increasing the probability of incremental JGB supply and a steeper long-end curve over 6-18 months; that is supportive for banks with asset-sensitive balance sheets, notably Mitsubishi UFJ (8306) and Sumitomo Mitsui Financial Group (8316), but raises valuation risk for long-duration domestic equities. Healthcare-equipment demand is not automatically a clean winner: reimbursement-rate pressure can force hospitals and care providers to defer capital purchases, making Terumo (4543) and Hoya (7741) more dependent on overseas growth than domestic aging narratives imply.

Consensus is likely to over-attribute this trend to a near-term consumption collapse. Labor scarcity can lift nominal wages, corporate automation spending and female labor-force participation before population decline dominates aggregate demand; Tokyo-focused real estate, urban transport and premium services may remain resilient while rural exposure deteriorates. The tradable near-term catalyst is wage and capex evidence in the next two quarterly results cycles, not demographic data itself; a sustained deterioration in machinery orders, automation-booking commentary, or bank net-interest-income guidance would falsify the relative-value thesis.

Key Decisions for Investors

• Initiate a 6-12 month pair: long FANUC (6954) and Keyence (6861) basket / short iShares MSCI Japan ETF (EWJ) in equal beta-adjusted notional. Target 10-15% relative outperformance from automation order growth and margin resilience; exit if Japan machinery orders contract for two consecutive releases or either company cuts full-year orders guidance.
• Accumulate Mitsubishi UFJ (8306) and SMFG (8316) on post-results weakness for a 6-18 month horizon, sized modestly against JGB volatility. The payoff is improving asset yields and deposit-franchise economics if the curve steepens; key risk is a policy-driven cap on lending spreads or a renewed BOJ easing cycle that compresses net interest income.
• Avoid using domestic aging alone as a reason to buy Japanese medtech. Place Terumo (4543) and Hoya (7741) on a watch list and only upgrade after confirmation that domestic procedure volumes and hospital capital budgets offset reimbursement pressure; a reimbursement revision or weaker hospital capex would be a negative catalyst.
• Do not add broad EWJ exposure solely on this development. For Japan beta, favor a barbell of automation exporters and megabanks over labor-intensive domestic retail, staffing and regional-service businesses during the next 1-3 months of wage and earnings updates.